Analysis of Surface Levels of IL-1 Receptors and Macrophage Scavenger Receptor I in Peripheral Immune Cells of Patients With Alzheimer Disease.


Journal

Journal of geriatric psychiatry and neurology
ISSN: 0891-9887
Titre abrégé: J Geriatr Psychiatry Neurol
Pays: United States
ID NLM: 8805645

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 26 4 2019
medline: 15 4 2020
entrez: 26 4 2019
Statut: ppublish

Résumé

Increased concentrations of interleukin 1 (IL-1) in the cerebrospinal fluid and serum of patients with Alzheimer disease (AD) reduced phagocytic capacity point to an inflammatory activation of mononuclear phagocytes in AD. Interleukin 1 receptors (IL-1R) and the macrophage scavenger receptor I (MSRI) are important players in IL-1 signaling and phagocytosis. In 20 patients with AD and 17 controls, IL-1RI, IL-1RII, and MSRI were assessed on peripheral blood mononuclear cells by flow cytometry. IL-1β, soluble IL-1 receptors, and IL-1R antagonist (IL-1Ra) were measured by enzyme-linked immunosorbent assay. The fraction of IL-1RI+ monocytes was increased by 10% and the expression of MSRI was reduced by 12% in AD. A 3.6% increased fraction of IL-1RI+ lymphocytes was accompanied by a 6.1% reduced expression of IL-1RII. The IL-1RI on monocytes and lymphocytes discriminated patients with AD with an accuracy of 0.79 and 0.75, respectively. The IL-1Ra was elevated in AD. Changes in the expression of IL-1 receptors and MSRI on peripheral blood cells fit to the concept of a proinflammatory state of the peripheral immune system. However, the observed differences are not strong enough to suggest their application as biomarkers for AD.

Identifiants

pubmed: 31018751
doi: 10.1177/0891988719841728
pmc: PMC6552296
doi:

Substances chimiques

Receptors, Interleukin-1 0
Receptors, Scavenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

211-220

Références

Life Sci. 1999;65(5):449-81
pubmed: 10462074
J Neurosci Res. 2004 Oct 15;78(2):151-6
pubmed: 15378607
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
J Neuroinflammation. 2005 Mar 11;2(1):9
pubmed: 15762998
J Alzheimers Dis. 2005 Jun;7(3):221-32; discussion 255-62
pubmed: 16006665
Neuron. 2006 Feb 16;49(4):489-502
pubmed: 16476660
Ann N Y Acad Sci. 2007 Oct;1113:173-7
pubmed: 17656565
Int Rev Neurobiol. 2007;82:205-33
pubmed: 17678963
Neurobiol Aging. 2010 Jan;31(1):17-24
pubmed: 18455839
J Neurol Sci. 2008 Sep 15;272(1-2):164-70
pubmed: 18597785
J Neurosci. 2008 Aug 13;28(33):8354-60
pubmed: 18701698
Immunol Rev. 2008 Dec;226:10-8
pubmed: 19161412
Brain Behav Immun. 2009 Jul;23(5):573-9
pubmed: 19258032
Nat Immunol. 2010 Feb;11(2):155-61
pubmed: 20037584
Biol Psychiatry. 2010 Nov 15;68(10):930-41
pubmed: 20692646
J Immunol. 2011 Dec 15;187(12):6539-49
pubmed: 22095718
Arch Neurol. 2012 Jul;69(7):824-31
pubmed: 22451159
J Clin Invest. 2012 Apr;122(4):1156-63
pubmed: 22466657
J Neuroimmunol. 2012 Oct 15;251(1-2):6-13
pubmed: 22743055
Cytotechnology. 2013 Oct;65(5):795-802
pubmed: 23440375
Nat Commun. 2013;4:2030
pubmed: 23799536
PLoS One. 2013 Sep 20;8(9):e75091
pubmed: 24073237
Semin Immunol. 2013 Dec 15;25(6):394-407
pubmed: 24246227
Immunity. 2013 Dec 12;39(6):1003-18
pubmed: 24332029
Clin Biochem. 2014 Mar;47(4-5):288-92
pubmed: 24389077
Mol Neurobiol. 2014 Oct;50(2):534-44
pubmed: 24567119
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Proc Natl Acad Sci U S A. 1989 Oct;86(19):7606-10
pubmed: 2508093
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
Nat Rev Neurosci. 2015 Jun;16(6):358-72
pubmed: 25991443
Proc Natl Acad Sci U S A. 2015 Sep 8;112(36):E5078-87
pubmed: 26305968
Biomark Med. 2016;10(1):1-4
pubmed: 26640978
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494
Aging Cell. 2017 Feb;16(1):27-38
pubmed: 27723233
J Immunol Res. 2017;2017:4626540
pubmed: 28293644
Psychopharmacol Bull. 1988;24(4):641-52
pubmed: 3249766
Nature. 1996 Aug 22;382(6593):716-9
pubmed: 8751442

Auteurs

Philipp Spitzer (P)

1 Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Johannes Weinbeer (J)

1 Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Martin Herrmann (M)

2 Department of Medicine III, Institute for Clinical Immunology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Timo Jan Oberstein (TJ)

1 Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Mateja Condic (M)

1 Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Piotr Lewczuk (P)

1 Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
3 Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland.

Johannes Kornhuber (J)

1 Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Juan Manuel Maler (JM)

1 Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH